ClinicalTrials.gg
CompletedNCT01253525Updated Jun 18, 2014Results posted

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

A Phase 1 interventional study of Ramucirumab (IMC-1121B ) and Paclitaxel in Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Adenocarcinoma with a site in Japan — 11 open to participants now, 18 under way, 7 of them phase 3. Adenocarcinoma · Japan.

Enrollment
32nd of 33
6 · median 250
Started
2010
with 2 others
Phase 1
9 of 33
2 open now
Registered
4th of 33
by date
Lead sponsor
3 of 33
Eli Lilly and Company

Among the 33 studies in Adenocarcinoma with a site in Japan, this one is the 32nd largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 1, and was the 4th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

11 of the 33 studies in Adenocarcinoma with a site in Japan are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Adenocarcinoma with a site in Japan, or all of them as a file.
02

Study summary

Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.

03

Conditions studied

  • Adenocarcinoma

Browse trials for

Keywords

  • Adenocarcinoma
  • Gastroesophageal Junction
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a histopathologically or confirmed diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma
  • Has an advanced or solid gastric adenocarcinoma that has failed standard therapy
  • Has resolution of all toxic effects of prior therapy, surgery, treatment with an agent or device, treatment monoclonal antibody or small molecule, and radiotherapy or chemotherapy.
  • Has adequate organ function
  • Eligible participants of (both sexes) agree to use adequate methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • Has undergone major surgery within 28 days prior to the study, or subcutaneous venous access device placement within 7 days prior to the study registration date
  • Has elective or planned surgery to be conducted during the trial
  • Has had treatment with an agent or device, an antineoplastic small molecule, or antineoplastic radiotherapy or chemotherapy
  • Was previously treated with a chemotherapy regimen containing nitrosoureas or mitomycin C
  • Has had treatment with an antineoplastic monoclonal antibody within 8 weeks prior to the study registration date
  • Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism prior to the study registration date
  • Has experienced any arterial thrombotic event, including myocardial infarction, cerebrovascular accident, or , within 6 months prior to the study date
  • Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents. (Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that the coagulation parameters (INR) ≤ 1.5, prothrombin time (PT) and partial thromboplastin time (PTT) or - Is receiving chronic therapy with nonsteroidal anti-inflammatory agents [Aspirin use at doses up to 325 milligrams/day (mg/day) is permitted]
  • Has significant bleeding disorders, vasculitis, history of postoperative bleeding complications, hemoptysis or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to the study date
  • Has a history of GI perforation and/or fistulae within 6 months prior to the study date
  • Has symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
  • Has uncontrolled arterial hypertension despite standard medical management.
  • Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to the study date
  • Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  • Has a serious illness or medical condition(s)
  • Is pregnant or lactating
  • Has received treatment with another investigational drug or participation in another interventional clinical trial within 28 days prior to the study date
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Ramucirumab (IMC-1121B ) and Pacitaxel

    Each treatment cycle is 4 weeks (28 days)

    Biological: Ramucirumab (IMC-1121B ) · Drug: Paclitaxel

Interventions

  • 8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle

    Also known as: LY3009806, IMC-1121B

  • 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1

    DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia \>5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc\>500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay \>1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay \>2 weeks between Cy 1 and Cy 2 due to persistent tox.

    Time frame: Cycle 1 of 28-day cycle

  2. Number of Participants With Adverse Events (AEs)

    The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Up to 47 weeks post baseline

  3. Number of Participants With Serious Adverse Events (SAEs)

    The number of participants who experienced SAEs that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Up to 47 weeks post baseline

Secondary outcomes

  1. Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1

    Cmax after a single dose of ramucirumab (IMC-1121B).

    Time frame: Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  2. Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)

    The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.

    Time frame: Cycle 1 through Cycle 5 (28-day cycles)

  3. Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1

    AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).

    Time frame: Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  4. Ramucirumab Half-Life (t1/2) for Cycle 1

    Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).

    Time frame: Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  5. Ramucirumab Clearance (CL) or Cycle 1

    CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] after a single dose of ramucirumab (IMC-1121B).

    Time frame: Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  6. Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1

    Vss \[distribution of ramucirumab (IMC-1121B) in the body at steady state\] after a single dose of ramucirumab (IMC-1121B).

    Time frame: Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  7. Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2

    Cmax after multiple doses of ramucirumab (IMC-1121B).

    Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  8. Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2

    AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).

    Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  9. Ramucirumab Half-Life (t1/2) for Cycle 2

    Terminal t1/2 \[the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%\] after multiple doses of ramucirumab(IMC-1121B).

    Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  10. Ramucirumab Clearance (CL) for Cycle 2

    CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] at steady state after multiple doses of ramucirumab (IMC-1121B).

    Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  11. Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2

    Vss \[distribution of ramucirumab (IMC-1121B) in in the body at steady state\] is not calculated for multiple doses of ramucirumab (IMC-1121B).

    Time frame: Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

  12. Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3

    Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.

    Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle

  13. Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3

    Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.

    Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle

  14. Ramucirumab Half-Life (t 1/2) for Cycle 3

    Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.

    Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle

  15. Ramucirumab Clearance (CL) for Cycle 3

    Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.

    Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle

  16. Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3

    Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.

    Time frame: Cycle 3: Pre-infusion, Day 1 of 28-day cycle

  17. Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4

    Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.

    Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle

  18. Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4

    Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

    Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle

  19. Ramucirumab Half-Life (t 1/2) for Cycle 4

    Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

    Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle

  20. Ramucirumab Clearance (CL) for Cycle 4

    Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

    Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle

  21. Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4

    Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

    Time frame: Cycle 4: Pre-infusion, Day 1 of 28-day cycle

07

Results

Posted Jun 18, 2014
Limitations and caveats
Cycle 3 and beyond pharmacokinetic sampling was collected per the protocol-defined limited sampling schedule.

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab + Paclitaxel
Started6
Received any quantity of study drug6
Completed6
Not completed0

Outcome measures

PrimaryNumber of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1

DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia \>5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc\>500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay \>1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay \>2 weeks between Cy 1 and Cy 2 due to persistent tox.

Time frame:
Cycle 1 of 28-day cycle
Reported as:
Number · participants
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
participantsRamucirumab + Paclitaxel
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 10
PrimaryNumber of Participants With Adverse Events (AEs)

The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Up to 47 weeks post baseline
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsRamucirumab + Paclitaxel
RAM-Related AEs Any Grade6
PAC-Related AEs Any Grade6
RAM-Related AEs Any Grade ≥32
PAC-Related AEs Any Grade ≥34
RAM-Related AEs Resulting in Death0
PAC-Related AEs Resulting in Death0
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

The number of participants who experienced SAEs that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Up to 47 weeks post baseline
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs)
participantsRamucirumab + Paclitaxel
RAM-Related SAEs2
PAC-Related SAEs2
SecondaryRamucirumab Maximum Serum Concentration (Cmax) for Cycle 1

Cmax after a single dose of ramucirumab (IMC-1121B).

Time frame:
Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · micrograms/milliliter (µg/mL)
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1
micrograms/milliliter (µg/mL)Ramucirumab + Paclitaxel
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1176 ± 46.6
SecondarySerum Anti-Ramucirumab Antibody Assessment (Immunogenicity)

The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.

Time frame:
Cycle 1 through Cycle 5 (28-day cycles)
Reported as:
Number · percentage of participants
Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)
percentage of participantsRamucirumab + Paclitaxel
Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)0
SecondaryRamucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1

AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).

Time frame:
Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · micrograms*hour/milliliter (µg*h/mL)
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1
micrograms*hour/milliliter (µg*h/mL)Ramucirumab + Paclitaxel
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 134100 ± NA
SecondaryRamucirumab Half-Life (t1/2) for Cycle 1

Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).

Time frame:
Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Median · hours (h)
Ramucirumab Half-Life (t1/2) for Cycle 1
hours (h)Ramucirumab + Paclitaxel
Ramucirumab Half-Life (t1/2) for Cycle 1190 (138 to 225)
SecondaryRamucirumab Clearance (CL) or Cycle 1

CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] after a single dose of ramucirumab (IMC-1121B).

Time frame:
Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · liters/hour (L/h)
Ramucirumab Clearance (CL) or Cycle 1
liters/hour (L/h)Ramucirumab + Paclitaxel
Ramucirumab Clearance (CL) or Cycle 10.0166 ± NA
SecondaryRamucirumab Steady State Volume of Distribution (Vss) for Cycle 1

Vss \[distribution of ramucirumab (IMC-1121B) in the body at steady state\] after a single dose of ramucirumab (IMC-1121B).

Time frame:
Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · liters (L)
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1
liters (L)Ramucirumab + Paclitaxel
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 13.27 ± NA
SecondaryRamucirumab Maximum Serum Concentration (Cmax) for Cycle 2

Cmax after multiple doses of ramucirumab (IMC-1121B).

Time frame:
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · micrograms/milliliter (µg/mL)
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2
micrograms/milliliter (µg/mL)Ramucirumab + Paclitaxel
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2284 ± 39.7
SecondaryRamucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2

AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).

Time frame:
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · micrograms*hour/milliliter (µg*h/mL)
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2
micrograms*hour/milliliter (µg*h/mL)Ramucirumab + Paclitaxel
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 241900 ± 951
SecondaryRamucirumab Half-Life (t1/2) for Cycle 2

Terminal t1/2 \[the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%\] after multiple doses of ramucirumab(IMC-1121B).

Time frame:
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Median · hours (h)
Ramucirumab Half-Life (t1/2) for Cycle 2
hours (h)Ramucirumab + Paclitaxel
Ramucirumab Half-Life (t1/2) for Cycle 2218 (218 to 218)
SecondaryRamucirumab Clearance (CL) for Cycle 2

CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] at steady state after multiple doses of ramucirumab (IMC-1121B).

Time frame:
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
Reported as:
Mean · liters/hour (L/h)
Ramucirumab Clearance (CL) for Cycle 2
liters/hour (L/h)Ramucirumab + Paclitaxel
Ramucirumab Clearance (CL) for Cycle 20.0136 ± 0.000342
SecondaryRamucirumab Steady State Volume of Distribution (Vss) for Cycle 2

Vss \[distribution of ramucirumab (IMC-1121B) in in the body at steady state\] is not calculated for multiple doses of ramucirumab (IMC-1121B).

Time frame:
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Maximum Serum Concentration (Cmax) for Cycle 3

Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.

Time frame:
Cycle 3: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3

Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.

Time frame:
Cycle 3: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Half-Life (t 1/2) for Cycle 3

Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.

Time frame:
Cycle 3: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Clearance (CL) for Cycle 3

Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.

Time frame:
Cycle 3: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Steady State Volume of Distribution (Vss) for Cycle 3

Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.

Time frame:
Cycle 3: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Maximum Serum Concentration (Cmax) for Cycle 4

Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.

Time frame:
Cycle 4: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4

Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

Time frame:
Cycle 4: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Half-Life (t 1/2) for Cycle 4

Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

Time frame:
Cycle 4: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Clearance (CL) for Cycle 4

Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

Time frame:
Cycle 4: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

SecondaryRamucirumab Steady State Volume of Distribution (Vss) for Cycle 4

Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.

Time frame:
Cycle 4: Pre-infusion, Day 1 of 28-day cycle

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab + Paclitaxel—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventRamucirumab + Paclitaxel
PneumoniaInfections and infestations2/6
Gastrointestinal haemorrhageGastrointestinal disorders1/6
Intestinal obstructionGastrointestinal disorders1/6
Decreased appetiteMetabolism and nutrition disorders1/6
Lymphangiosis carcinomatosaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6
MeningismNervous system disorders1/6
Most frequent other events
Showing 10 of 52
Most frequent other events
EventRamucirumab + Paclitaxel
EpistaxisRespiratory, thoracic and mediastinal disorders5/6
NeutropeniaBlood and lymphatic system disorders4/6
RashSkin and subcutaneous tissue disorders4/6
NauseaGastrointestinal disorders3/6
PyrexiaGeneral disorders3/6
Decreased appetiteMetabolism and nutrition disorders3/6
ProteinuriaRenal and urinary disorders3/6
AlopeciaSkin and subcutaneous tissue disorders3/6
AnaemiaBlood and lymphatic system disorders2/6
DiarrhoeaGastrointestinal disorders2/6

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Ramucirumab + Paclitaxel
Mean57.6 ± 15.50
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab + Paclitaxel
Female1
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab + Paclitaxel
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab + Paclitaxel
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Ramucirumab + Paclitaxel
Japan6
08

Study locations

3 sites
  • ImClone Investigational Site
    Chiba, 277-8577, Japan
  • ImClone Investigational Site
    Osaka, 569-8686, Japan
  • ImClone Investigational Site
    Osaka, 589-5811, Japan
09

References and documents

Publications

  • Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015 May;20(5):493-4. doi: 10.1634/theoncologist.2014-0440. Epub 2015 Apr 17. PubMed 25888272 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2010
First posted
Dec 3, 2010
Start
Nov 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Jun 18, 2014
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01253525
Responsible party
Sponsor
First posted
Dec 3, 2010
Start date
Nov 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Jun 18, 2014
Last update
Jun 18, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion